Tandem Diabetes announces issuance of patent related to infusion pump safety
Tandem Diabetes Care announced the issuance of U.S. Patent No. 9,715,327 titled "Preventing Inadvertent Changes in Ambulatory Medical Devices". The patent relates to important safety features for the prevention of inadvertent changes in touchscreen enabled ambulatory infusion pumps, including insulin pumps. The touchscreen may be on the pump itself or be in wireless communication with a pump. The user interface for the t:slim, t:slim X2, t:flex and t:slim G4 Insulin Pumps were developed based on information and feedback collected from thousands of interviews, focus groups and online surveys to understand what people with diabetes, their caregivers and healthcare providers wanted in order to improve diabetes therapy management. The company also utilized human factors research in its development process so that users can more successfully operate their insulin pump in its intended environment. U.S. Patent No. 9,715,327 is scheduled to expire in 2033. The company has a related U.S. continuation application on file, as well as a pending application in Europe.